Autres langues HBM Holdings Limited

Actions

2142

KYG4403H1002

Marché Fermé - Hong Kong S.E. Autres places de cotation 10:09:05 07/06/2024			Varia. 5j.	Varia. 1 janv.
1,38 ^HKD	+0,73 %		-5,48 %	-28,87 %

23/05	Les actions de Hong Kong glissent encore vers le bas en raison de la réduction des taux d'intérêt et des inquiétudes concernant l'inflation	MT
23/05	L'unité de HBM Holdings et AstraZeneca signent un accord de licence et d'option pour un traitement ciblé du cancer ; les actions augmentent de 16 %.	MT

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Hong Kong Shares Slip Further Down Amidst Interest Rate Reduction, Inflation Worries	23/05
HBM Holdings Unit, AstraZeneca Sign License, Option Agreement for Targeted Cancer Treatment; Shares Rise 16%	23/05
Nona Biosciences Announces Global License and Option Agreement with AstraZeneca for Monoclonal Antibody to be Developed into Novel Tumor Targeted Therapies	23/05
Nona Biosciences Co., Ltd and AstraZeneca Enters into License and Option Agreement	23/05
HBM Holdings Returns to Profitability in 2023	02/04
Harbour BioMed Reports Full Year 2023 Financial Results	28/03
HBM Holdings Limited Reports Earnings Results for the Full Year Ended December 31, 2023	28/03
HBM Holdings Subsidiary Signs Antibody-Drug Conjugate Discovery Collaboration Deal	27/02
HBM Holdings Gets US FDA Clinical Trial Approval for Anti-Tumor Medication	24/01
Harbour BioMed Announces IND Clearance for HBM9027 in the U.S	24/01
HBM to Swing to 2023 Profit	19/01
Harbour BioMed Announces Positive Profit Alert	19/01
HBM Holdings Limited Provides Earnings Guidance for the Year Ended 31 December 2023	19/01
HBM Holdings Limited commences an Equity Buyback Plan for 76,842,891 shares, representing 10% of its issued share capital, under the authorization approved on June 8, 2023.	19/12
Harbour BioMed's Wholly-owned Subsidiary Nona Biosciences Enters into a Global License Agreement with Pfizer for HBM9033, an MSLN-Targeted Antibody-Drug Conjugate	15/12
HBM Holdings Unit Nona Biosciences Signs Licensing Deal with Seagen for Tumor Medication; Shares Fall 5%	15/12
HBM Holdings Limited Announces Results of the Phase Iii Clinical Trial, Which Demonstrated That the Efficacy in the Primary and Secondary Endpoints of Batoclimab	01/12
HBM Holdings Limited Announces Executive Changes	19/10/23
HBM Swings to Profit in H1; Shares Up 6%	29/08/23
HBM Gets US FDA Clearance to Hold Anti-Tumor Drug Trials in US	29/08/23

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues HBM Holdings Limited

Actions

2142

KYG4403H1002

Autres langues

Filtres